To assess the long-term safety and efficacy of the BAROSTIM NEO System in trial (NCT01471834) participants.
Eligibility
Sex
ALL
Min age
21 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
* Actively participating in the Neo Non-Randomized Hypertension Study.
* Have signed a revised approved informed consent form for continued participation in this study.
Exclusion Criteria:
* Treating physician decision that the subject should not continue with therapy.
Primary outcome measure(s)
To access long-term adverse events in participants implanted with the BAROSTIM NEO System. — For the duration of the study, up to 10 years. Ascertain the type, frequency, severity and timing of long-term adverse events in participants implanted with the device, while providing a viable treatment option to participants currently implanted with CVRx's BAROSTIM NEO System.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.